CMS: Data shows moderate support for Provenge use

All of the available data for Dendreon's Provenge prostate cancer vaccine shows 'moderate' support for its use, according to a government analysis. CMS, which meets with outside advisers next Wednesday to discuss paying for the vaccine, analyzed all the available evidence for the therapy that has had drawn scrutiny for its large price tag amid praise from cancer advocates. Company shares, which closed at $34.83, rose 5.4 percent to $36.70 in after-hours trading. Also, Dendreon says it has applied for FDA approval to essentially quadruple the capacity of its New Jersey factory. Story | News

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.